Non-invasive Radio Surgical Equipment for Treatment of Obesity & Diabetes

World's cutting-edge treatment technology featuring our latest generation system for late-stage tumors treatment



Metron Metabolic Medical Inc.

Capital Raise up to $15mm via REG D 506c

Metron元创

CONTENTS

01 Company Introduction

02 Market Background

03 Project Introduction

04 Project Planning and Financing Plan

METRON

PART 01

Company Introduction

1.1 Company Introduction

Metron Metabolic Medical Inc., a Wyoming corporation ("Metron" or "Company") is a medical technology Company with innovation and research & development as the core, committed to building a global leading medical service platform.

Our Co-Founder Professor Shipeng Song, invented the world's first rotary gamma knife and obtained US FDA certification in 1999[1] for late-stage tumor treatment. Our vision is to commercialize Professor Song's latest generation radio surgical equipment, which can treat late-stage tumors, but we are focusing on new applications in treating obesity and diabetes. We plan to initially focus on the US market. The U.S. weight management market size was estimated at USD $37.86 billion in 2023 and is expected to grow at a CAGR of ~11% from 2024 to 2030, according to Grand View Research.[2] The global market in 2023 for Anti-Obesity Medications ("AOMs") reached ~$6 billion on an annualized basis. By 2030, it could grow by more than 16 times to ~$100 billion, according to Goldman Sachs Research.[3]

Current treatment for obesity using GLP-1 can be effective, but has many side effects,[4] such as Dizziness, Mild tachycardia (increased heart rate), Infections. Headaches, Indigestion (upset stomach) to more severe ones, including Pancreatitis. Medullary thyroid cancer, Acute (sudden) kidney injury and Worsening diabetes-related retinopathy. Our proposed one-time treatment, can be completed within one hour, which we believe can significantly reduce obesity with a "zap" in a small, targeted area of the brain, with almost zero side effects.

1.2 Founder & Chief Scientist: the Pioneer of the Non-invasive Metabolic Surgery Industry



Song Shipeng[5] The Founder and Chief Scientist

- Former researcher at Harvard MGH Gordon Medical Center
- Former Adjunct Professor at Huazhong University of Science and Technology and Shanghai University of Science and Technology
- “OUR rotary Gamma Knife” received 1997 Level 1 Science & Technology Advancement Level 1 Award by the predecessor of National Medical Products Administration
- Awarded "Leading Talents in Science and Technology" and "Top-notch Talents" by the Shanghai
- Has developed or been part of team developing a large number of domestic and foreign patented technologies (mostly invention patents)
- We believe Prof. Song created a number of both Global and China's first medical devices.**
- Created the Chinese Gamma Knife Industry, known as the "Father of China ’ s Gamma Knife"

Host of other companies that Mr. Song has founded over the years

OUR 奥沃国际

Management believes Mr. Song Invented the world's first rotary gamma knife. First Chinese Company to obtain

US FDA certification[1]

CCM 泰和诚 CONCORD MEDICAL

Acquired a subsidiary of OUR – one of China’s leading medical service group

NYSE: CCM[6]

E1 一体医疗 ET MEDICAL

We believe Prof. Song invented a) the world’s 1st full-body hyperthermia device and b) China’s 1st full body phototherapy device
E1 is a wholly-owned subsidiary of Zhongzhu Medical

China A Share: 600568[7]

We believe it is one of the most technologically advanced Gamma Knife company in China (treating late-stage tumor). Hygeia Healthcare[8]

Star

HKex:06078[9]

A number of leading technology and project reserves

世鹏实验室 SONG'S LAB


PART 02

Market Background

2.1 Obesity has Become the Primary Health Concern among Countries

Obesity is a chronic disease with excess body fat. The body mass index (BMI) (weight (kg) / height (m^2) is usually used at home and with people's health care providers.

WHO defines BMI>25 as overweight and BMI>30 as obesity;[10] In China, BMI>24 is usually defined as overweight and BMI>28 as obesity. According to the recommendations of the International Diabetes Federation and the Chinese Diabetes Society, waistline (cm) is used to diagnose central obesity. Usually, male waistline >90cm can be diagnosed as central obesity, and female waist circumference is over 80cm or 85cm.



Picture Source: Wikipedia[11]

From the perspective of the causes of obesity, in addition to genetic factors, with the rapid development of society and economy, people's behavior changes, which constitutes an important inducement of obesity. According to NIH, causes of obesity and overweight include:[12]

- Lack of physical activity
- Unhealthy eating behaviors
- Not getting enough good-quality sleep
- High amounts of stress
- Health conditions
- Genetics, Medicines

Most of the causes of obesity are related to bad dietary habits. A variety of food supply, the growing popularity of fast food, snacks temptation, irregular meals, psychological pressure increase "revenge eating", and the reduction of physical labor caused by the development of mechanization and automation, fewer legs and more wheels, reduction of housework and other factors lead to the imbalance of people ' s energy metabolism. And obesity has become the main cause of a variety of chronic disease!

The U.S.A government has made the prevention and treatment of obesity a national strategy.[13]

7

2.2 Obesity and Diabetes: Slowly Approaching the Human Disaster

Obesity is estimated to be the fifth-leading risk factor for death worldwide.[14]


Obese people not only have a 2-3 times higher risk of diabetes than those with normal weight, but also have a significantly higher risk of coronary heart disease, stroke, hypertension, osteoarthritis, gout, sleep apnea syndrome, endocrine disorders and some tumors. Obesity can accelerate the aging process and shorten life expectancy by an average of 8 years.

Complications

Diabetes and its costly complications, including blindness, amputation and dialysis, can impose a significant long-term burden on national health budgets and the finances of every family.

Treatment costs

In many countries, the cost of treatment for patients with diabetes can consume more than half of a family's total income. In many countries, only the cost of care for diabetes may account for more than 20% of the total health budget.



Dr. Margaret Chan, former Director General of the World Health Organization, shouted in the keynote speech at the 47th meeting of the National Academy of Medicine in Washington:[15]

Obesity and diabetes, has been slowly approaching the human disaster!

2.3 Global Adult Obesity Rate by 2035



Source: [Article by Jenna Moon at semafor.com](#)[16]

9

2.4 Overweight is highly associated with the risk of multiple diseases, and obesity is strongly associated with the risk of multiple cancers

At present, obesity has been recognized as a disease by WHO, and weight gain is highly related to the risk of type II diabetes, hypertension, cardiovascular disease and other diseases. Among them, the increase in the risk of type II diabetes is very obvious when BMI is within the overweight range. According to the research and analysis of IARC, obesity is significantly related to 13 primary cancers[17] (esophageal adenocarcinoma, multiple myeloma, cardiac cancer, colon cancer, rectal cancer, gallbladder cancer, pancreatic cancer, breast cancer, endometrial cancer, ovarian cancer, kidney cancer, meningioma, and thyroid cancer), with sufficient evidence. The increase of BMI will significantly increase the risk of esophageal adenocarcinoma, male colorectal cancer, biliary system and pancreatic cancer, premenopausal endometrial cancer, renal cancer and multiple myeloma.

As BMI increases over 25, the risks increase for several health conditions, including:[18]

Heart disease	Type 2 diabetes
Hypertension	Stroke
Osteoarthritis	Sleep apnea
Some cancers (endometrial, breast, colon, kidney, gallbladder, liver)	
Depression and anxiety	Difficulty with physical movement
Lower quality of life	

Risks of cardiovascular disease relative to body mass index and waist circumference[19]

Body Mass Index	Waist circumference (cm/inches)	
	≤ 102/40" (Men) ≤ 88/35" (Women)	> 102/40" (Men) > 88/35" (Women)
• 18.5 or less (underweight) • 18.5 - 24.9 (normal weight)	Normal risk of CVD	Increased risk of CVD
• 25 - 29.9 (overweight)	Increased risk	High risk
• 30 - 34.9 (mildly obese)	High risk	Very high risk
• 35 - 39.9 (obese)	Very high risk	Very high risk
• 40 or greater (extremely obese)	Extremely high risk	Extremely high risk

2.5 The simultaneous treatment of obesity and diabetes is an international consensus

The International Diabetes Federation officially recognized metabolic surgery as a method of treating obesity with type II diabetes. In the same year, the diabetes Branch of the Chinese Medical Association and the Surgery Credit Association of the Chinese Medical Association also reached a consensus on metabolic surgery for type II diabetes

Non-invasive Metabolic Surgery

Metabolic surgery

2009 — 2011 — 2016 — **NOW**

In 2009, the American Diabetes Society officially classified metabolic surgery as one of the measures to treat obesity with type 2 diabetes[20] in its guidelines for the treatment of type 2 diabetes

In May 2016, the official journal of the American Diabetes Association published the "Metabolic surgery for type 2 diabetes: joint statement of international diabetes organizations". The statement was drafted by 48 international authoritative experts (two of whom are Chinese scholars) from 16 countries and 9 disciplines in the world. It recommended that metabolic surgery be included in the clinical treatment path of type 2 diabetes, and was recognized by 45 international diabetes organizations. Thus, the role of metabolic surgery in the treatment of type 2 diabetes has been further established

The treatment method we use, although completely different from the current treatment ideas and methods in the medical community, has the same purpose: to reduce the patient's appetite and reduce food intake.

Our method is simply simpler, completely non-invasive, and has better results! So, we call this treatment method "non-invasive metabolic surgery"

2.6 Obesity and diabetes are currently the main surgery and treatment methods

01

Laparoscopic gastric bypass surgery

Only suitable for patients with extreme obesity above BMI 45 or BMI 35 above with other diseases caused by obesity, such as diabetes, heart disease, etc

02

Laparoscopic gastric band band surgery

Suitable for BMI 35-45 patients

03

General water balloon surgery for ordinary weight loss

weakness

Surgical Risk **Complication** **High Requirements for Doctors** **Expensive**

Weight-loss Surgery Side Effects[21]

Side effects of weight-loss surgery, also called metabolic and bariatric surgery, may include bleeding, infection, leaking from the site where the sections of the stomach, small intestine, or both are stapled or sewn together diarrhea, and blood clots in the legs that can move to the lungs or heart.

Surgical treatment of the digestive system

Although the above types of operations are very mature, but the requirements for doctors and hospitals are relatively high fees and very expensive! So compared with the number of patients for decades, the number of surgery is still very small, completely unable to stop the rapid increase in patients

Bariatric surgery (or weight-loss surgery) changes the structure of your digestive system to help you lose weight. In the US the average bariatric surgery costs $7,400 to $33,000[22] before insurance coverage.

12

2.7 Metabolic surgery & non-invasive metabolic surgery comparison

Contrast item	Metabolic surgery	Metron Metabolic Non-invasive Surgery
The difficulty of surgery	☆☆☆☆☆	☆ The treatment process standard is unified and one-click treatment
Surgical conditions	The patient was overweight and laborious to carry Surgical instruments, beds and other need to be special, need to cut the super thick fat layer It is time-consuming and laborious, and has a surgical risk	Autonomous development of the robot bed, patients can stand up up and down the bed, non-invasive
Surgical duration	A few hours	Few minutes
Anaesthesia	General anesthesia	No anesthesia
Complications[23]	With BMI over 30, being overweight, your risks rapidly rise to over 65%. This means the risks of surgery outweigh the benefits of the surgery, and it is you, who will suffer the complications.	None to date as our machine technology still in development but we believe there should be no or very little complications
Treatment costs[22]	In the US the average bariatric surgery costs $7,400 to $33,000	$35,000 to $50,000
Whether reversible	no	yes
Patients' willingness to treat	Low	High

PART 03

Project Introduction

3.1 Introduction of treatment methods and principles

Metron元创

Radiobiology

Radiobiology is a science that studies the effects of various rays on histiocyte of various organisms. For example, X-ray，γ-ray. When rays and neutron rays act on histiocyte, the activity of histiocyte will undergo various wonderful changes due to the biological effects of radiation

The results of these three effects in histiocyte are completely different! This is the foundation of radiation therapy. After further studying how the different results of these three effects in histiocyte are applied in clinical treatment, we found that using these three effects of radiobiology, we can use the physical means of radiotherapy to treat more diseases, which can greatly expand the application field of radiotherapy!

Dose range (depending on treatment site and disease type)



Radiation Damage
Above 6 ~ 100 Gy*




Radio-inhibition
1 ～ 25 Gy*



Radioactivation
0.01 ～ 5 Gy*

* Based on Prof. Song's research on amount of Gray (Gy).

The biological effects of radiation vary depending on the amount of radiation absorbed by the organism, radiotherapy can be classified into:



15

3.2 Rationale of radioinhibition therapy

Metron元创


According to the theory of radiobiology, when the radiation dose applied to the target tissue gradually decreases, reaching a certain threshold range, the radiation will no longer have a destructive effect on histiocyte, but will significantly reduce the "biological activity" of histiocyte, producing an "inhibitory effect"

After one week of treatment

About a week after treatment, the cellular activity of the target tissue has been suppressed by radiation, and the uncontrollable "strong appetite symptoms" have significantly decreased, gradually reducing appetite to normal, fundamentally solving the problem of abnormal appetite. Of course, the sequela is that eating is not so delicious

After 8-12 months of treatment

Since the histiocyte in the target area are only inhibited by radiation, the "activity" of the histiocyte in the target area inhibited by radiation gradually recovers, so it will not cause irreversible results to the histiocyte in the target area



When "inhibition dose" is selected to irradiate specific "target tissues", the "activity level" of target histiocyte can be significantly reduced, thus changing various diseases caused by the "activity level change" of cells, so as to achieve the purpose of treating diseases

For obese patients, after the "abnormally excited appetite center" is irradiated with suppressed doses of radiation, the cell activity greatly decreases to the precise set value, and the abnormally excited symptoms disappear, resulting in a decrease in the patient's appetite

Most patients can complete the treatment in one time

16

3.3 Independent developed equipment:

X001 MRX Baymax

Integrated Intracranial Radiosurgical Treatment System with MRI and 4MV Accelerator



Integrated magnetic resonance imaging and 4MV accelerator*

0.35T magnetic resonance imaging system, high-definition, high-speed 3D imaging+AI cloud system

Dose and target sites

Focus dose rate: 18Gy/min (4Mv electron accelerator, X-ray)
5 sets of collimators with diameters of: Φ 3，6，12，18、24mm*

Positioning

Multimodal image fusion, reverse computing, high-speed cloud computing, network TPS software system
Non-invasive, fast, and high-precision positioning system*

Radiotherapy system

The AI radiotherapy cloud system "no chef design" allows small and medium-sized hospitals to provide the highest level of treatment services.
Multi axis rotating focus "focal to skin ratio" >200:1 (the larger the ratio, the better the focus position accuracy and dose accuracy. Real time verification of the system*

Scope of treatment

Treatment of obesity and diabetes, intracranial tumors, AVM, trigeminal neuralgia and more than 20 classic mature diseases, as well as dozens of functional diseases*

**Company's own internal estimates for treatment protocol.*

3.4 Comparison with the similar type of products**

Metron元创

brand	Metron	Eleckta	ZAP-X
			
Name	X001MRX	ICON	ZAP-X
Radiographic source	4 Mv X-ray	The Co60 γ -ray	2.7 Mv X-ray
System positioning accuracy	≤0.15mm	0.15mm	
Focal Dose Rate	18 Gy / min (X-ray)	3 Gy / min (γ -ray)	1500MU/min
Iatrotechnique	Double track rotation focus	Multi-source focus	Multi-angle static irradiation
Image guidance	MRI / center coaxial coplanar with therapy	External CBCT system Separation from centers such as therapy	X-CBCT system, placed inside the equipment
Target Site	Φ 3,6,12,18,24mm	Φ 4,8,14,18mm	Φ 4,5,7,8,10,12.5,15,20,25mm
Treatment Bed	Six-axis robot treatment bed and the patient can be up and down the bed standing	Common 3D treatment bed	Common 3D treatment bed
SRS fixed position	3D for the printing of a facial mask	Invasive head positioning frame	plastic mask
Scope of indications	Head and neck Cancer Metabolic diseases: obesity, type II diabetes, weight loss, etc	Head and facial various tumors, AVM, trigeminal neuralgia and other more than 10 diseases, of which tumors accounted for 82%	It is mainly for head and facial tumor indications


*** Based on Company's own research*

3.5 Summary

Metron元创

Clear treatment methods

Control and influence on the patient's appetite " has become the most important purpose of various treatments



The appetite center of the brain

The vast majority of obese patients eat a lot because their appetite center is "abnormally excited" and can not completely control their strong appetite, which leads to a serious excess of calories, fat accumulation and development of obesity patients, of which more than 60% are accompanied by diabetes and multiple complications.

Due to the high intelligence of 【X001 MRX】, the main operations are completed through the network and computer, making it very simple to use, without trauma and other sugery risks. The requirements for hospitals and doctors are also greatly reduced. Therefore, the treatment becomes easier and is easily popularized and promoted around the world. While completing the treatment of the two major diseases, it will also become the most effective and cost-effective prevention method for various chronic diseases such as high blood pressure, hyperlipidemia, and heart disease

Complete the "non-invasive treatment" in one go

Once using X001MRX， accurately irradiate the target (appetite center) and provide a "radiation inhibition dose" to accurately "suppress" its "abnormal excitation" at the set value

Curative Effect


After treatment, the patient's appetite began to decrease and their intake significantly decreased. This not only effectively cured obesity, but also completed the treatment of multiple complications such as diabetes!

Prospect

Next, by utilizing this treatment network platform, we can also collaborate with cosmetic surgery institutions to implement "efficient non-invasive weight loss" for a large number of high-income beauty and physical fitness populations. Not only is the weight loss effect first-class, but also due to its simple and completely non-invasive operation, the market scale is even larger!

19

3.6 Business Model



20

PART 04

Project &Financing Plan

4.1 Project Promotion Schedule*

Metron元创

job content	the first year				the next year			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Preliminary project preparation and personnel organization								
prototype engineering design								
Parts customization								
Image component development								
operating software development								
Preparation of final assembly hospital								
Prototype final assembly and debugging								
Third-party type inspection								
FDA (Head and Neck Cancer Clinical exemption)								
Clinical validation of animal experiments (obesity)								

22

4.2 Estimation of project capital requirements

- Management believes only a 510K certification is needed for our equipment to treat tumor. We should not need to redo a full clinical trial.
- After completion of prototype, we can jointly apply for $30 - $50 million USD for the NIH project fund together with US universities and scientific research institutions;
- After signing potential new contract with a U.S. based cooperating hospital, we believe we can begin to work with an equipment leasing company to finance the manufacturing of the machines.
- We may also choose to use the US Investment Immigration (EB-5) policy to address the funding for large-scale treatment centers; if no EB-5 funding is available the goal would be to partner with treatment center operators.

4.2 Direct CapEx and Operations Capital Needs

Metron元创

	(thousand USD)	Remarks
Total Projected Expenses	12,000	Two-years budget
1. Equipment fee		
(a) Software development fee	429	
(b) Cost of building 2 prototypes	2,286	Machinery + electronic control + MRI + ray source + industrial design + computer
2. Inspection, evidence collection, patent filings	2,286	
3. Fixed Assets	713	Physical measurement and testing instruments, hoisting and assembly equipment, special computer, truck
4. Salaries		
(a) China based personnel	771	Annual salary of ~￥360,000 / 15 people (~$50,000 as USD = 7.30 Yuan 12.27.24)
(b) US based personnel	1,500	Annual salary of ~$150,000 / 10 people
(c) Welfare & Benefits costs	1,446	
5. Marketing Expense	343	
6, Factory and Office Expense	1,000	US factory is 2000 square meters, including 300 square meters of office, 1700 square meters of production, requiring a standard industrial plant with trusses, with a height of 12-15 meters. China office 300 m 2
7. Working capital	1,226	

Two Separate Financing plans

- Financing Amount: Total = US$15 million in capital (Terms TBD)

  $15 million for building prototype, standard formulation, animal experiment, clinical trial, FDA certification and market development (2 years budget)

- a) $15 million private placement or

  b) $3 million private placement and a $12 million IPO

4.3 Use of Proceeds ($5million, $10million, $15million)

Metron元创

(In thousands USD)

Total Projected Expenses	5,000	10,000	15,000
Equipment	1,500	2,715	2,715
Inspection, evidence collection, patent filings	500	2,286	2,286
Fixed Assets	250	714	714
Salaries	1,140	1,912	3,717
Marketing Expense	-	343	343
Factory and Office Expense	300	900	1,000
Working Capital	20	50	2,635
IPO Preperation	800	100	120
Broker Commission – Private Placement	450	900	1,350
Offering Related Expense – Private Placement	40	80	120

Information Links

[1]Page 4 US FDA certification in 1999: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=k970647

[2]Page 4 Grand View Research: https://www.grandviewresearch.com/industry-analysis/us-weight-management-market-report

[3]Page 4 Goldman Sachs Research: https://www.goldmansachs.com/insights/articles/anti-obesity-drug-market

[4]Page 4 GLP-1 can be effective, but has many side effects: https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists

[5]Page 5 Baidu Encyclopedia: https://baike.baidu.com/item/%E5%AE%8B%E4%B8%96%E9%B9%8F/8793410?fr=ge_ala

Selected translations: Professor Shipeng Song - Former Adjunct Professor at Huazhong University of Science and Technology and Shanghai University of Science and Technology

- 1995 formed Shenzhen OUR International Technology Development Co Ltd. He developed China's first world-leading large-scale medical equipment, the rotary Gamma Knife, and created China's Gamma Knife industry. He is known as the "Father of Chinese Gamma Knife".
- 1999 formed Shenzhen ET Smart Technologies Ltd
- 2003 formed “Song Lab”. Shanghai Shipeng Laboratory Technology Development Co., Ltd

**Page 5 Full List of International Patents available in the Company’s Virtual Data Room.

[6]Page 5 Concord Medical Services Holdings Limited (NYSE: CCM) stock quote: https://finance.yahoo.com/quote/CCM/

[7]Page 5 Zhongzhu Healthcare Holding Co., Ltd (Shanghai:600568) stock quote: https://finance.yahoo.com/quote/600568.SS/

[8]Page 5 October 30, 2019 news titled “Hygeia Medical Planned Hong Kong IPO, Shipeng Song, Father of Gamma Knife in China is a Co-Founder”:

https://news.futunn.com/post/4125433/hygia-healthcare-plans-to-go-to-hong-kong-for-an?level=3&data_ticket=1734076171209372

[9]Page 5 Hygeia Healthcare Holdings Co Ltd (HKG:06078) stock quote:

https://www.google.com/search?q=6078+%E6%B5%B7%E5%90%89%E4%BA%9A%E5%8C%BB%E7%96%97&sca_esv=f712e055a0066755&sxsrf=ADLYWILaPmeBygAlYeCmgrHxyxInY38u0g%3A1734076297068&source=hp&ei=iedbZ8Fu76S-vQ-Z2I_BDw&iflsig=AL9hbdgAAAAAZ1v1mSbAJ2o87r482G3dZWMadpLDCuLo&oq=%E6%B5%B7%E5%90%89%E4%BA%9A%E5%8C%BB%E7%96%97&gs_lp=Egdnd3Mtd2l6Ig_mtbflkInkuprljLvnlpcqAggGMgUQABiABDILEC4YgAQY0QMYxwEyBRAAGO8FMgUQABjvBTIFEAAY7wUyBRAAGO8FMgYQABgFGB5IzYIBUABYAHAAeACQAQCYAUqgAUqqAQExuAEByAEA-AEC-AEBmAIBoAJRmAMAkgcBMaAH7wQ&sclient=gws-wiz

[10]Page 7 WHO defines BMI>25 as overweight and BMI>30 as obesity: https://www.who.int/health-topics/obesity#tab=tab_1

[11]Page 7 Wikipedia photo: https://en.wikipedia.org/wiki/Body_mass_index

[12]Page 7 According to NIH, causes of obesity and overweight include: https://www.nhlbi.nih.gov/health/overweight-and-obesity/causes

[13]Page 7 US Government actions: https://www.cdc.gov/obesity/php/about/obesity-strategies-what-can-be-done.html

[14]Page 8 Obesity is estimated to be the fifth-leading risk factor for death worldwide:

https://pmc.ncbi.nlm.nih.gov/articles/PMC9884894/#:~:text=Obesity%20is%20estimated%20to%20be,risk%20factor%20for%20death%20worldwide.&text=The%20global%20prevalence%20of%20overweight,over%20the%20past%20few%20decades.&text=Globally%2C%20overweight%20is%20prevalent%20in,of%20whom%20are%20clinically%20obese.

[15]Page 8 Obesity and diabetes: the slow-motion disaster Keynote address at the 47th meeting of the National Academy of Medicine:

https://www.who.int/director-general/speeches/detail/obesity-and-diabetes-the-slow-motion-disaster-keynote-address-at-the-47th-meeting-of-the-national-academy-of-medicine

[16] Page 9 Global Adult Obesity Rate by 2035: https://www.semafor.com/article/03/03/2023/the-global-obesity-crisis-explained-in-three-maps

[17] Page 10 According to the research and analysis of IARC, obesity is significantly related to 13 primary cancers: https://www.iarc.who.int/news-events/iarc-contributes-to-who-european-regional-obesity-report-2022/

[18] Page 10 As BMI increases over 25, the risks increase for several health conditions, including:

https://rotel.pressbooks.pub/overweight-bodies/chapter/__unknown__-4/

[19] Page 10 Risks of cardiovascular disease relative to body mass index and waist circumference:

https://copingwithcholesterol.ca/shape-up/identify-your-healthy-weight/

[20]Page 11 In 2009, the American Diabetes Society officially classified metabolic surgery as one of the measures to treat obesity with type 2 diabetes:

https://pmc.ncbi.nlm.nih.gov/articles/PMC10011678/

[21]Page 12 Weight-loss Surgery Side Effects:

https://www.niddk.nih.gov/health-information/weight-management/bariatric-surgery/side-effects

[22]Page 12 The average bariatric surgery costs:

https://www.goodrx.com/conditions/weight-loss/bariatric-surgery-costs

[23]Page 13 Complications:

https://mydoctor.kaiserpermanente.org/ncal/article/the-trouble-with-fat-or-why-being-overweight-leads-to-surgery-complications-dsa-plastic-surgery-1556195

This Investor Presentation ("Presentation") contains only preliminary information regarding our Company and should be read in conjunction with the entire Private Placement Offering Memorandum ("Memorandum" and/or Subscription Agreement including all the Risk Factors mentioned therein. An investment in this Offering is highly speculative, an investor could experience an entire loss of principal, and that the investment is illiquid for an indefinite period of time.

Summary of Risk Factors Include:

- **Because this Offering will be conducted on a "best efforts" basis and there is no minimum requirement to close, there can be no assurance that we can raise the money we need, and earlier investors are more at risk than later stage investors.**
- **We are an early-stage business and may not have the ability to continue as a going concern. Additionally, we are currently a foreign based Chinese operating business and as such may encounter tariffs, and other geopolitical issues with working within the United States and other Foreign Markets.**
- **We have a limited operating history, not yet generating any revenues and there can be no assurance of commercial success of the products and underlying technology.**
- **The Company may have future capital needs and there exists the uncertainty of additional financing, including future potential dilution.**
- **If we are unable to protect our intellectual property, the value of our brand and other intangible assets may be diminished, and the Company may be adversely affected.**
- **We will have broad discretion over the use of the proceeds we receive in the Offering and may not apply the proceeds in a manner that increases the value of your investment.**
- **Our projections and forward-looking information may prove to be incorrect.**
- **There might be unanticipated obstacles to the execution of our business plan.**
- **We may not be able to execute on the business plan and planned growth and expansion.**
- **We may have competition from other companies.**
- **We depend on key personnel, and if we fail to retain and attract skilled management and other key personnel, our business may be harmed.**
- **No public market for our securities.**
- **An investment in the Company is highly speculative in nature and the Company cannot assure you of a return on your investment.**

The Company and our officers and representatives may from time to time make, "forward-looking statements" within the meaning of the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate", "intend", "plan", "goal", "seek", "believe", "project", "estimate", "expect", "strategy", "future", "likely", "may", "should", "will" and similar references to future periods.

Examples of forward-looking statements include, among others, statements we make regarding: guidance relating to revenues, gross margins, operating income, net income and net income per share; expected operating results, such as revenue growth and earnings; anticipated levels of capital expenditures for the fiscal year; current or future volatility in the credit markets and future market conditions; our belief that we have sufficient liquidity to fund our business operations as planned; expectations of the effect on our financial condition of claims, litigation, contingent liabilities and governmental and regulatory investigations and proceedings; strategy for growth, product development, market position, financial results and reserves; strategy for risk management. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.

Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: economic and financial conditions, continued volatility in the capital or credit markets; the adequacy of our cash flow and earnings and other conditions; developments and changes in laws and regulations. Investors are strongly encouraged to review all Risk Factors and the entire Private Placement Memorandum ("Memorandum") and/or Subscription Agreement(s) before investing.

Any forward-looking statement made by us in this document is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

This Presentation is intended for general solicitation under the exemption for Regulation D 506(c) but does not constitute an offer to sell or a solicitation of an offer to buy any securities. The information contained herein has been prepared by Management of the Company to assist interested parties in making their evaluation of the Company and does not purport to contain all of the information that a party may desire. In all cases, interested parties should conduct and rely on their own investigation and analysis of the Company and the data set forth herein.

THESE ARE HIGHLY SPECULATIVE AND ILLIQUID SECURITIES, WHICH INVOLVE A HIGH DEGREE OF RISK. ONLY THOSE INVESTORS WHO CAN BEAR THE LOSS OF THEIR ENTIRE INVESTMENT SHOULD INVEST IN THESE SECURITIES AND INVESTORS MUST ALSO BE WILLING TO HOLD THESE SECURITIES FOR AN INDEFINITE PERIOD OF TIME.

An offer of to buy these securities can only be made by obtaining the Company's confidential Memorandum and/or Subscription Agreement(s) interested parties should only rely on the information contained in such Offering Materials. Confidential and Proprietary Information. All information contained herein is the confidential and proprietary information of the Company and as such, cannot be disclosed, reproduced or distributed without the prior written consent of the CEO of the Company or its Placement Agent CIM Securities, LLC.

PLACEMENT AGENT DISCLOSURE:

This Disclosure Statement is being provided to you to describe the relationship among Metron Metabolic Medical Inc. (the "Company"), and CIM Securities, LLC ("CIM"), relating to your investment in the Company. CIM is a registered broker dealer member of FINRA and SIPC. The Company and CIM are not related parties. The Company and CIM have entered into an Engagement Letter Agreement ("Agreement") under which CIM provides investment banking advisory services and solicits investor prospects of this common equity, preferred equity or convertible notes (equity-linked) capital raise ("Securities") for the Company and the Company compensates CIM for referring investors to the Company. The exact structure for this capital raise is yet to be determined from a Lead Investor. For each person or entity (including "You", the "Investor") that is solicited by CIM pursuant to the terms and conditions of the Agreement, who acquires or commits to acquire an interest in the Company, within a defined time period, as a result of such solicitation, Company shall pay, or cause to be paid, to CIM and any licensed Selling Agents it may be working with a cash fee of up to Seven Percent (7%) of gross transaction proceeds to the Company as well as receive Five Percent (5%) of any equity shares purchased in the form of Common Stock Placement Agent Warrants ("PA Warrants") that contain a five (5) year term and CIM has a cashless exercise provision exercisable at the same price per Share for the Warrants which are for the Company's Common Stock. and no other success fee-based compensation. The Company also agreed to pay CIM an engagement fee and reimbursable expenses equal to $25,000 in connection with this Offering.

This compensation to CIM does not in any way affects the number of shares that would be issued to you if you acquired such interest without the solicitation of CIM or any of its Selling Agents. These fees may cause a conflict between your interests and CIM's. Registered Representatives of CIM and their family members may be or may become investors in this Transaction or any other Company issuance. This may also cause a conflict of interest in your investment. Registered Representatives of CIM and Selling Agents may be engaged to solicit other transactions at higher or lower compensation agreements, which may also be a conflict of interest to your solicitation for this investment. The Firm may also provide you with other comparable investment opportunities that should be considered and discussed with your representative, prior to making any investments. Please review the Customer Relationship Summary (CRS) of CIM Securities.

Investor Contact

Aaron Tsai

Email: aaron@mascapital.com

Mobile & WhatsApp: +886-916-906-398

CIM Securities, LLC

Jack Myers

Email: JackMyers@cimsecurities.com

Office 619-749-2460

Company Address:

6th Floor, No, 1, Building 8, Hongqiao Times Square, Qingpu District, Shanghai 201702, Shanghai, China

Metron元创



Thank you!



Pr Proprietary